Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for XBiotech Inc. (XBIT : NSDQ)
 
 • Company Description   
XBiotech Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing True Human(TM) monoclonal antibodies for treating diseases. XBiotech Inc. is based in AUSTIN, United States.

Number of Employees: 92

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.18 Daily Weekly Monthly
20 Day Moving Average: 183,983 shares
Shares Outstanding: 30.49 (millions)
Market Capitalization: $96.95 (millions)
Beta: 0.98
52 Week High: $8.32
52 Week Low: $2.50
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 11.19% 5.17%
12 Week 10.42% -7.37%
Year To Date -19.49% -24.59%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
5217 WINNEBAGO LANE
-
AUSTIN,TX 78744
USA
ph: 512-386-2900
fax: 512-386-5505
swhitehurst@xbiotech.com http://www.xbiotech.com
 
 • General Corporate Information   
Officers
John Simard - President and Chief Executive Officer
Angela Hu - Principal Financial Officer and Principal Accounti
W. Thorpe McKenzie - Director
Jan-Paul Waldin - Director
Peter Libby - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 98400H102
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/11/25
Share - Related Items
Shares Outstanding: 30.49
Most Recent Split Date: (:1)
Beta: 0.98
Market Capitalization: $96.95 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.55
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -9.09%
vs. Previous Quarter: -5.88%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -21.14
12/31/24 - -19.75
ROA
06/30/25 - -
03/31/25 - -19.55
12/31/24 - -18.08
Current Ratio
06/30/25 - -
03/31/25 - 29.15
12/31/24 - 11.56
Quick Ratio
06/30/25 - -
03/31/25 - 29.15
12/31/24 - 11.56
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 5.73
12/31/24 - 5.98
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©